China's Sinovac, With High-level Government Backing, Could Win Global Race To Market A/H1N1 Vaccine
This article was originally published in PharmAsia News
Executive Summary
BEIJING - With the strong support of China's central government and Beijing health authorities, leading vaccine maker Sinovac Biotech could become the first to cross the finish line in the worldwide race to produce a defense to the A/H1N1 pandemic